Literature DB >> 7741836

Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.

.   

Abstract

BACKGROUND: The Advanced Glaucoma Intervention Study (AGIS) is a multicenter, randomized clinical trial designed (1) to determine the better of two surgical management strategies for glaucoma when medical treatment alone no longer adequately controls the disease and (2) to clarify the clinical course and prognosis of open-angle glaucoma after surgical interventions have begun. The investigators of this study have developed quantitative methods to assess the test reliability and measure the severity of glaucomatous visual field defects with the 24-2 threshold program of the Humphrey Visual Field Analyzer. This report details these methods and presents information about long-term fluctuation during a time interval short enough to render change due to disease unlikely.
METHODS: In AGIS, reliability assessment of automated visual field tests is based on the number of questions asked; percent of fixation losses, false-positive responses, and false-negative responses; and amount of short-term fluctuation. The AGIS visual field defect score is based on the number and depth of clusters of adjacent depressed test sites in the upper and lower hemifields and in the nasal area of the total deviation printout of the threshold program single-field test STATPAC-2 analysis. The score ranges from 0 (no defect) to 20 (all test sites deeply depressed). The fluctuation in score between two tests obtained during an interval preceding AGIS surgical interventions, ranging from 1 day to 6 weeks on 756 eyes of 562 patients, is analyzed.
RESULTS: The scores of the first visual field tests, which determined eligibility for the study, range from 1 to 17. Large positive or negative interest fluctuations (absolute changes of 4 or more) occurred in the second tests for 16% of eyes; more scores improved (11%) than worsened (5%). The frequency of large fluctuations tended to increase as the time interval between tests increased. Absolute interest fluctuations were independent of age.
CONCLUSION: For visual field tests obtained with the automated perimeter, AGIS investigators have developed objective, quantitative methods of scoring test reliability and severity of glaucomatous field loss. For 16% of eyes, long-term fluctuations were large enough (> or = 4 points) to suggest improvement or worsening of the glaucomatous defect even though the interval in which the fluctuations occurred was short enough (median time, approximately 1 week) to render changes in disease status unlikely.

Entities:  

Mesh:

Year:  1994        PMID: 7741836

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  103 in total

1.  Variability across the optic nerve head in scanning laser tomography.

Authors:  J C H Tan; D F Garway-Heath; R A Hitchings
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

2.  Spatial pattern of glaucomatous visual field loss obtained with regionally condensed stimulus arrangements.

Authors:  Ulrich Schiefer; Eleni Papageorgiou; Pamela A Sample; John P Pascual; Bettina Selig; Elke Krapp; Jens Paetzold
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

3.  Single-nucleotide polymorphisms and glaucoma severity.

Authors:  Catey Bunce; Roger A Hitchings; Shomi S Bhattacharya; Ordan J Lehmann
Journal:  Am J Hum Genet       Date:  2003-06       Impact factor: 11.025

4.  Optical coherence tomography shows progressive local nerve fiber loss after disc hemorrhages in glaucoma patients.

Authors:  Christoph Kernstock; Janko Dietzsch; Kai Januschowski; Ulrich Schiefer; M Dominik Fischer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-25       Impact factor: 3.117

5.  Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.

Authors:  John L Keltner; Chris A Johnson; Richard A Levine; Juanjuan Fan; Kimberly E Cello; Michael A Kass; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2005-09

6.  [Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?].

Authors:  A G M Jünemann; C Huchzermeyer; R Rejdak
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

7.  Bayes' theorem applied to perimetric progression detection in glaucoma: from specificity to positive predictive value.

Authors:  Nomdo M Jansonius
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-01       Impact factor: 3.117

8.  Improving the repeatability of Heidelberg retina tomograph and Heidelberg retina tomograph II rim area measurements.

Authors:  N G Strouthidis; E T White; V M F Owen; T A Ho; D F Garway-Heath
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

9.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

Review 10.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.